HER2 mediates clinical resistance to the KRAS(G12C) inhibitor sotorasib, which is overcome by co-targeting SHP2. Ho CSL, Tuns AI, Schildhaus HU, Wiesweg M, et al. Eur J Cancer 2021;159:16-23.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ho CSL, Tuns AI, Schildhaus HU, Wiesweg M, et al. HER2 mediates clinical resistance to the KRAS(G12C) inhibitor sotorasib, which is overcome by co-targeting SHP2. Eur J Cancer 2021;159:16-23.
PMID: 34715459